A phase II trial of personalized peptide vaccination in castration-resistant prostate cancer patients: prolongation of prostate-specific antigen doubling time

[1] Vollmer RT(1998)The dynamics of prostate specific antigen in hormone refractory prostate carcinoma: an analysis of cancer and leukemia group B study 9181 of megestrol acetate Cancer 83 1989-1994

[2] Dawson NA(2007)Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer J Clin Oncol 25 3965-3970

[3] Vogelzang NJ(1999)Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer J Natl Cancer Inst 91 244-251

[4] Armstrong AJ(2006)Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99–16 Natl Cancer Inst 98 516-521

[5] Garrett-Mayer E(2010)Improved endpoints for cancer immunotherapy trials J Natl Cancer Inst 102 1388-1397

[6] Ou Yang YC(2010)IMPACT Study Investigators: Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 411-422

[7] Carducci MA(2004)TAX 327 Investigators: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 1488-1490

[8] Tannock I(2004)Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 1513-1520

[9] de Wit R(2011)Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy Clin Cancer Res 17 907-917

[10] Eisenberger M(2003)Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination Prostate 57 80-92

[1] Vollmer RT(1998)The dynamics of prostate specific antigen in hormone refractory prostate carcinoma: an analysis of cancer and leukemia group B study 9181 of megestrol acetate Cancer 83 1989-1994

[2] Dawson NA(2007)Prostate-specific antigen and pain surrogacy analysis in metastatic hormone-refractory prostate cancer J Clin Oncol 25 3965-3970

[3] Vogelzang NJ(1999)Post-therapy serum prostate-specific antigen level and survival in patients with androgen-independent prostate cancer J Natl Cancer Inst 91 244-251

[4] Armstrong AJ(2006)Evaluation of prostate-specific antigen declines for surrogacy in patients treated on SWOG 99–16 Natl Cancer Inst 98 516-521

[5] Garrett-Mayer E(2010)Improved endpoints for cancer immunotherapy trials J Natl Cancer Inst 102 1388-1397

[6] Ou Yang YC(2010)IMPACT Study Investigators: Sipuleucel-T immunotherapy for castration-resistant prostate cancer N Engl J Med 363 411-422

[7] Carducci MA(2004)TAX 327 Investigators: Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer N Engl J Med 351 1488-1490

[8] Tannock I(2004)Docetaxel and estramustine compared with mitoxantrone and prednisone for advanced refractory prostate cancer N Engl J Med 351 1513-1520

[9] de Wit R(2011)Tumor regression and growth rates determined in five intramural NCI prostate cancer trials: the growth rate constant as an indicator of therapeutic efficacy Clin Cancer Res 17 907-917

[10] Eisenberger M(2003)Induction of cellular and humoral immune responses to tumor cells and peptides in HLA-A24 positive hormone-refractory prostate cancer patients by peptide vaccination Prostate 57 80-92